Morgan Stanley Maintains Equal-Weight on Anterix, Lowers Price Target to $41
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Nigel Dally has maintained an Equal-Weight rating on Anterix (NASDAQ:ATEX) and lowered the price target from $42 to $41.
August 04, 2023 | 9:15 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Anterix and lowered the price target from $42 to $41.
The news directly pertains to Anterix (NASDAQ:ATEX) as Morgan Stanley has maintained an Equal-Weight rating on the company and lowered the price target. This could potentially influence investor sentiment and the stock's price, but the impact is neutral as the rating has not changed, only the price target has been slightly lowered.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100